---
document_datetime: 2025-05-21 15:33:12
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pedea-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: pedea-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.2970713
conversion_datetime: 2025-12-14 15:42:01.783218
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Pedea

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I HUMAN AND VETERINARY MEDICINAL | 21/05/2025                          |                                             | SmPC and PL                      |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000264965                     | PRODUCTS - C.I.z Other variation - Accepted C.I.z - To update sections 4.4 and 4.8 of the SmPC and sections 2 and 4 of the PL to implement the wording related to the Severe Skin Reaction safety signal (DRESS syndrome) in line with PSUSA EMEA/H/C/PSUSA/00001712/202307 and PSUSA/00010345/201702.   |            |     |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000255542 | B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted                                                                                                                       | 13/03/2025 | N/A |